Oppenheimer Asset Management Inc. Sarepta Therapeutics, Inc. Transaction History
Oppenheimer Asset Management Inc.
- $7.94 Billion
- Q4 2024
A detailed history of Oppenheimer Asset Management Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 4,079 shares of SRPT stock, worth $260,321. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,079
Previous 4,457
8.48%
Holding current value
$260,321
Previous $556,000
10.97%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding SRPT
# of Institutions
530Shares Held
85.3MCall Options Held
1.55MPut Options Held
1.35M-
Black Rock Inc. New York, NY10.3MShares$659 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$580 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA8.7MShares$555 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X04.33MShares$276 Million0.28% of portfolio
-
State Street Corp Boston, MA4.07MShares$260 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $5.59B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...